Clinical Trials Sponsored by ISA Pharmaceuticals

Total 22342 results

ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Squamous Cell Carcinoma of the Oropharynx | HPV16 Positive

Netherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Regeneron Pharmaceuticals
ISA Pharmaceuticals B.V.

Active, not recruiting

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Cervical Cancer

Spain, Korea, Republic of, Netherlands, Brazil, Belgium, United States, Italy, Russian Federation
ISA Pharmaceuticals
Dutch Cancer Society

Completed

Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer (CervISA)

Cervical Cancer

Germany, Netherlands, Belgium
Erasmus Medical Center
ISA Pharmaceuticals B.V.

Recruiting

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

Chronic Hepatitis b

Netherlands
Teva Pharmaceuticals USA

Completed

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Dyspareunia

United States, El Salvador, Honduras
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

Rosacea
Taro Pharmaceuticals USA

Completed

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

An Open-Label Study to Assess Safety

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Teva Pharmaceuticals USA

Completed

Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Benazepril HCl 40 mg Tablets, Fasting

Healthy

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

Rosacea

United States
Taro Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

Onychomycosis

United States
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Atopic Dermatitis

United States
Taro Pharmaceuticals USA

Completed

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Dermatitis, Atopic

United States
Taro Pharmaceuticals USA

Completed

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Psoriasis
Taro Pharmaceuticals USA

Completed

Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Teva Pharmaceuticals USA

Terminated

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Depressive Disorder

United States
Taro Pharmaceuticals USA

Completed

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Pediculosis

United States
Taro Pharmaceuticals USA

Completed

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Pediculosis

United States
Taro Pharmaceuticals USA

Completed

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

Psoriasis

United States
Taro Pharmaceuticals USA

Terminated

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis (BNF-0909)

Interdigital Tinea Pedis
Taro Pharmaceuticals USA

Completed

Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Atopic Dermatitis
Taro Pharmaceuticals USA

Completed

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis

Actinic Keratosis
Taro Pharmaceuticals USA

Terminated

A Study of T2000 in Essential Tremor

Essential Tremor

Canada
Taro Pharmaceuticals USA

Completed

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

Lice Infestations

United States
Taro Pharmaceuticals USA

Terminated

Pilot Efficacy Study of T2000 in Myoclonus Dystonia

Myoclonus

Canada
Taro Pharmaceuticals USA

Terminated

T2000 in Essential Tremor - Open Label Continuation

Essential Tremor

Canada
Teva Pharmaceuticals USA

Completed

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study

Healthy

Canada
Teva Pharmaceuticals USA

Completed

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

Healthy

United States
Teva Pharmaceuticals USA

Completed

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

Healthy

United States
Teva Pharmaceuticals USA

Completed

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Valacyclovir 1000 mg Tablet Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Topiramate 25 mg Capsules Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions

Healthy

Canada

3

Subscribe